EE200300249A - GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon - Google Patents
GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioonInfo
- Publication number
- EE200300249A EE200300249A EEP200300249A EEP200300249A EE200300249A EE 200300249 A EE200300249 A EE 200300249A EE P200300249 A EEP200300249 A EE P200300249A EE P200300249 A EEP200300249 A EE P200300249A EE 200300249 A EE200300249 A EE 200300249A
- Authority
- EE
- Estonia
- Prior art keywords
- combination
- reductase inhibitors
- aldose reductase
- gaba agonists
- gaba
- Prior art date
Links
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 title 1
- 239000003288 aldose reductase inhibitor Substances 0.000 title 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25044800P | 2000-11-30 | 2000-11-30 | |
PCT/IB2001/002214 WO2002043763A2 (en) | 2000-11-30 | 2001-11-19 | Combination of gaba agonists and aldose reductase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200300249A true EE200300249A (et) | 2003-10-15 |
Family
ID=22947799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200300249A EE200300249A (et) | 2000-11-30 | 2001-11-19 | GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon |
Country Status (34)
Country | Link |
---|---|
US (1) | US6720348B2 (sk) |
EP (1) | EP1337272A2 (sk) |
JP (1) | JP2004514700A (sk) |
KR (1) | KR20030059287A (sk) |
CN (1) | CN1477976A (sk) |
AP (1) | AP2001002359A0 (sk) |
AR (1) | AR031432A1 (sk) |
AU (1) | AU2002215160A1 (sk) |
BG (1) | BG107812A (sk) |
BR (1) | BR0115776A (sk) |
CA (1) | CA2430309A1 (sk) |
CR (1) | CR6962A (sk) |
CZ (1) | CZ20031387A3 (sk) |
DO (1) | DOP2001000294A (sk) |
EA (1) | EA200300433A1 (sk) |
EC (1) | ECSP034629A (sk) |
EE (1) | EE200300249A (sk) |
HR (1) | HRP20030419A2 (sk) |
HU (1) | HUP0302555A3 (sk) |
IL (1) | IL155710A0 (sk) |
IS (1) | IS6787A (sk) |
MA (1) | MA26965A1 (sk) |
MX (1) | MXPA03004871A (sk) |
NO (1) | NO20032387D0 (sk) |
OA (1) | OA12413A (sk) |
PA (1) | PA8534201A1 (sk) |
PE (1) | PE20020598A1 (sk) |
PL (1) | PL365378A1 (sk) |
SK (1) | SK6092003A3 (sk) |
SV (1) | SV2003000752A (sk) |
TN (1) | TNSN01170A1 (sk) |
UY (1) | UY27044A1 (sk) |
WO (1) | WO2002043763A2 (sk) |
ZA (1) | ZA200303340B (sk) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ332762A (en) | 1996-07-24 | 2000-09-29 | Warner Lambert Co | Isobutylgaba and its derivatives for the treatment of pain |
US6696407B1 (en) * | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
US20030162754A1 (en) * | 2001-12-17 | 2003-08-28 | Tufts University | Use of GABA and GABAB agonists |
WO2003105864A1 (en) * | 2002-06-13 | 2003-12-24 | Board Of Regents, The University Of Texas System | Methods and compositions involving aldose reductase inhibitors |
KR20090118994A (ko) * | 2002-12-13 | 2009-11-18 | 워너-램버트 캄파니 엘엘씨 | 하부요로증상을 치료하기 위한 알파-2-델타 리간드 |
US20080318908A1 (en) * | 2002-12-17 | 2008-12-25 | Trustees Of Tufts College | Use of gaba and gabab agonists |
EP1480631B1 (en) * | 2002-12-20 | 2007-08-01 | Dynogen Pharmaceuticals Inc. | Methods of treating non-painful bladder disorders using alpha2-delta- subunit calcium channel modulators |
KR100742001B1 (ko) * | 2003-03-21 | 2007-07-23 | 다이노젠 파마세우티컬스, 인코포레이티드 | 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법 |
KR20050036195A (ko) * | 2003-10-15 | 2005-04-20 | 고재영 | 신규한 망막병증 치료제 조성물 |
US20110092566A1 (en) * | 2004-11-19 | 2011-04-21 | Srivastava Satish K | Treatment of cancer with aldose reductase inhibitors |
WO2007053596A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
MX2008013137A (es) | 2006-04-11 | 2008-10-21 | Novartis Ag | Compuestos organicos. |
WO2008077597A1 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors |
EP2848252A3 (en) | 2007-03-23 | 2015-06-17 | The Board of Regents of the University of Texas System | Aldose reductase inhibitors for use in treating uveitis |
US20090270490A1 (en) * | 2008-04-24 | 2009-10-29 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibition |
JP2010043063A (ja) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
EP2309858A4 (en) | 2008-07-31 | 2011-09-14 | Dekel Pharmaceuticals Ltd | COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES |
EA016904B1 (ru) * | 2008-09-06 | 2012-08-30 | Бионевия Фармасьютикалс, Инк. | Новый холиновый сокристалл эпалрестата |
CN103547261A (zh) | 2010-12-23 | 2014-01-29 | 德克萨斯大学系统董事会 | 用于治疗copd的方法 |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US20180161388A1 (en) * | 2015-05-18 | 2018-06-14 | Beth Israel Deaconess Medical Center, Inc. | Substance p, mast cell degranulation inhibitors, and peripheral neuropathy |
MX2019012476A (es) * | 2017-04-21 | 2020-02-12 | Hoffman Steven | Composiciones y metodos para tratar la retinopatia. |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
EP3955918A1 (en) | 2019-04-17 | 2022-02-23 | COMPASS Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
CH427803A (de) | 1963-12-06 | 1967-01-15 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Isoxazolderivates |
DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US3960927A (en) | 1975-03-18 | 1976-06-01 | Richardson-Merrell Inc. | Olefinic derivatives of amino acids |
FR2319338A1 (fr) | 1975-08-01 | 1977-02-25 | Synthelabo | Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent |
US4130714A (en) | 1977-05-23 | 1978-12-19 | Pfizer Inc. | Hydantoin therapeutic agents |
IE47592B1 (en) * | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
CS234018B2 (en) | 1979-06-01 | 1985-03-14 | Wellcome Found | Method of 3,5-diammino-6-1,2,4-triazine derivatives making |
JPS5745185A (en) | 1980-07-21 | 1982-03-13 | Eisai Co Ltd | Hydantoin derivative and its preparation |
US4791126A (en) | 1980-08-22 | 1988-12-13 | Ono Pharmaceutical Co., Ltd. | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredients |
JPS5740478A (en) * | 1980-08-22 | 1982-03-06 | Ono Pharmaceut Co Ltd | Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative |
FR2492258A1 (fr) | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
CA1176269A (en) | 1981-03-02 | 1984-10-16 | Kazimir Sestanj | N-naphthoylglycine derivatives |
US4436745A (en) | 1982-04-15 | 1984-03-13 | Alcon Laboratories, Inc. | Method of inhibiting aldose reductase activity |
US4438272A (en) | 1982-04-15 | 1984-03-20 | Alcon Laboratories, Inc. | Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US5066659A (en) | 1984-10-30 | 1991-11-19 | Pfizer Inc. | Spiro-heteroazalones for treatment of diabetic complications |
DK288385D0 (da) * | 1985-06-26 | 1985-06-26 | Novo Industri As | Aminosyrederivater |
GB8524663D0 (en) | 1985-10-07 | 1985-11-13 | Fujisawa Pharmaceutical Co | Quinazoline derivatives |
US4939140A (en) * | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
AU602641B2 (en) | 1986-04-17 | 1990-10-18 | Senju Pharmaceutical Co., Ltd. | Thiolactam-N-acetic acid derivatives, their production and use |
EP0264586B1 (en) | 1986-08-28 | 1991-04-03 | Sanwa Kagaku Kenkyusho Co., Ltd. | Hydantoin derivatives for treating complications of diabetes |
US4771052A (en) * | 1987-02-05 | 1988-09-13 | Hoechst-Roussel Pharmaceuticals, Inc. | Tetrahydropyrido[3',4':4,5]pyrrolo[2,3-c]quinolines and their use as hypotensive agents |
GB8801037D0 (en) | 1988-01-18 | 1988-02-17 | Plessey Co Ltd | Improvements relating to fuel supply systems |
US5252572A (en) * | 1988-02-03 | 1993-10-12 | Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. | Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same |
US4996204A (en) * | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
US4980357A (en) | 1990-03-01 | 1990-12-25 | Pfizer Inc. | Azolidinedione derivatives |
US5037831A (en) | 1990-05-21 | 1991-08-06 | American Home Products Corporation | Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors |
US5236945A (en) * | 1990-06-11 | 1993-08-17 | Pfizer Inc. | 1H-indazole-3-acetic acids as aldose reductase inhibitors |
GB9016978D0 (en) | 1990-08-02 | 1990-09-19 | Ici Plc | Acetamide derivatives |
US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
EP0662962A1 (en) * | 1992-09-28 | 1995-07-19 | Pfizer Inc. | Substituted pyrimidines for control of diabetic complications |
FR2774908B1 (fr) * | 1998-02-17 | 2000-06-23 | Centre Nat Rech Scient | Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne |
GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
US6350769B1 (en) * | 1999-02-24 | 2002-02-26 | The Regents Of The University Of California | Gaba alpha receptors mediate inhibition of T cell responses |
DK1041068T3 (da) * | 1999-04-01 | 2004-05-10 | Pfizer Prod Inc | Compounds for treating and preventing diabetic complications |
NZ514813A (en) * | 1999-04-08 | 2004-12-24 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
-
2001
- 2001-11-19 HU HU0302555A patent/HUP0302555A3/hu unknown
- 2001-11-19 EE EEP200300249A patent/EE200300249A/xx unknown
- 2001-11-19 CA CA002430309A patent/CA2430309A1/en not_active Abandoned
- 2001-11-19 CZ CZ20031387A patent/CZ20031387A3/cs unknown
- 2001-11-19 JP JP2002545733A patent/JP2004514700A/ja not_active Withdrawn
- 2001-11-19 AP APAP/P/2001/002359A patent/AP2001002359A0/en unknown
- 2001-11-19 WO PCT/IB2001/002214 patent/WO2002043763A2/en not_active Application Discontinuation
- 2001-11-19 OA OA1200300138A patent/OA12413A/en unknown
- 2001-11-19 SK SK609-2003A patent/SK6092003A3/sk not_active Application Discontinuation
- 2001-11-19 BR BR0115776-0A patent/BR0115776A/pt not_active IP Right Cessation
- 2001-11-19 KR KR10-2003-7007221A patent/KR20030059287A/ko not_active Application Discontinuation
- 2001-11-19 EP EP01983740A patent/EP1337272A2/en not_active Withdrawn
- 2001-11-19 AU AU2002215160A patent/AU2002215160A1/en not_active Abandoned
- 2001-11-19 IL IL15571001A patent/IL155710A0/xx unknown
- 2001-11-19 EA EA200300433A patent/EA200300433A1/ru unknown
- 2001-11-19 CN CNA018195954A patent/CN1477976A/zh active Pending
- 2001-11-19 PL PL01365378A patent/PL365378A1/xx not_active Application Discontinuation
- 2001-11-19 MX MXPA03004871A patent/MXPA03004871A/es unknown
- 2001-11-26 DO DO2001000294A patent/DOP2001000294A/es unknown
- 2001-11-27 PE PE2001001187A patent/PE20020598A1/es not_active Application Discontinuation
- 2001-11-28 AR ARP010105542A patent/AR031432A1/es not_active Application Discontinuation
- 2001-11-28 UY UY27044A patent/UY27044A1/es not_active Application Discontinuation
- 2001-11-29 US US09/997,039 patent/US6720348B2/en not_active Expired - Fee Related
- 2001-11-29 TN TNTNSN01170A patent/TNSN01170A1/fr unknown
- 2001-11-30 SV SV2001000752A patent/SV2003000752A/es unknown
- 2001-11-30 PA PA20018534201A patent/PA8534201A1/es unknown
-
2003
- 2003-04-14 IS IS6787A patent/IS6787A/is unknown
- 2003-04-24 CR CR6962A patent/CR6962A/es not_active Application Discontinuation
- 2003-04-30 ZA ZA200303340A patent/ZA200303340B/en unknown
- 2003-05-13 BG BG107812A patent/BG107812A/bg unknown
- 2003-05-20 MA MA27166A patent/MA26965A1/fr unknown
- 2003-05-22 HR HR20030419A patent/HRP20030419A2/hr not_active Application Discontinuation
- 2003-05-27 NO NO20032387A patent/NO20032387D0/no not_active Application Discontinuation
- 2003-05-28 EC EC2003004629A patent/ECSP034629A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200300249A (et) | GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon | |
EE200300248A (et) | GABA agonistide ja sorbitooldehüdrogenaasi inhibiitorite kombinatsioon | |
EE200300470A (et) | Aldoosreduktaasi püridasinooninhibiitorid | |
NO20041582L (no) | Antistoffinhibitorer av GDF-8 og anvendelse derav | |
ATE370938T1 (de) | Pro-pharmakon von cox-2-inhibitoren | |
NO20032668L (no) | Gyraseinhibitorer og anvendelser derav | |
EE200200715A (et) | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena | |
EE200300362A (et) | PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid | |
EE200300361A (et) | PDE4 isosüümide inhibiitoritena kasutatavad eetriderivaadid | |
IS6934A (is) | Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar | |
EE200200576A (et) | Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena | |
AR028253A1 (es) | Inhibidores de la glucogeno fosforilasa | |
EE200200426A (et) | PDE4 isosüümide inhibiitoritena kasulikud pürimidiinkarboksamiidid | |
NO20030406D0 (no) | Ikke-steroidale inflammasjonshemmere | |
DK1307263T3 (da) | Hidtil ukendt anvendelse af lipaseinhibitorer | |
BRPI0208558A2 (pt) | preparado de combinação de estrogênio-gestagênio e uso | |
DK1458447T3 (da) | Kombination af cytokrom-p450-beroende proteasinhibitorer | |
AR028281A1 (es) | Derivados de 2-(arilalquilamino) pirimidona y derivados de 2-(heteroaroarilalquilamino) pirimidona | |
ITMI20021391A1 (it) | Nitroderivati di inibitori della cicloossigenasi-2 | |
PT1392670E (pt) | Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina | |
IL157935A0 (en) | Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors | |
DK1337271T3 (da) | Kombination af GABA-agonister og sorbitoldehydrogenaseinhibitorer | |
SI1337271T1 (en) | Combination of gaba agonists and sorbitol dehydrogenase inhibitors | |
SE0004239D0 (sv) | New use of an inhibitor | |
AR027946A1 (es) | Uso de los inhibidores il-18 |